by April Breyer Menon | Feb 29, 2020
February was a busy month for the FDA in the field of biosimilars: On February 3, 2020, the FDA and FTC issued a joint statement regarding their enhanced collaboration to support the adoption of biosimilars and interchangeables. On February 3, 2020, the FDA...
by April Breyer Menon | Feb 6, 2020
Download PDF Download...
by April Breyer Menon | Jan 22, 2020
Venable partner Ha Kung Wong spoke at the Specialty Therapies and Biosimilars Conference as part of a panel that discussed biosimilar litigation and patent issues. He focused on the impact of inter partes reviews (IPRs) and post grant reviews (PGRs) on how patents...
by April Breyer Menon | Jan 7, 2020
Download PDF Download...
by April Breyer Menon | Dec 12, 2019
The Supreme Court on December 11, 2019 unanimously ruled in Peter v. NantKwest, Inc., No. 18-801, that the United States Patent and Trademark Office (USPTO) cannot shift the fees of its attorneys and paralegals to litigants in district court proceedings brought under...